|
1
|
Mackay HJ, Brady MF, Oza AM, Reuss A,
Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA,
Pfisterer J, et al: Prognostic relevance of uncommon ovarian
histology in women with stage III/IV epithelial ovarian cancer. Int
J Gynecol Cancer. 20:945–952. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan JK, Teoh D, Hu JM, Shin JY, Osann K
and Kapp DS: Do clear cell ovarian carcinomas have poorer prognosis
compared to other epithelial cell types? A study of 1411 clear cell
ovarian cancers. Gynecol Oncol. 109:370–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K,
Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al:
Clear cell carcinoma of the ovary: A retrospective multicentre
experience of 254 patients with complete surgical staging. Br J
Cancer. 94:1369–1374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takano M, Tsuda H and Sugiyama T: Clear
cell carcinoma of the ovary: Is there a role of histology-specific
treatment? J Exp Clin Cancer Res. 31:532012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winter WE III, Maxwell GL, Tian C, Carlson
JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and
McGuire WP: Gynecologic Oncology Group Study: Prognostic factors
for stage III epithelial ovarian cancer: A Gynecologic Oncology
Group Study. J Clin Oncol. 25:3621–3627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ho CM, Huang YJ, Chen TC, Huang SH, Liu
FS, Chien CC Chang, Yu MH, Mao TL, Wang TY and Hsieh CY: Pure-type
clear cell carcinoma of the ovary as a distinct histological type
and improved survival in patients treated with
paclitaxel-platinum-based chemotherapy in pure-type advanced
disease. Gynecol Oncol. 94:197–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guan B, Wang TL and Shih IeM: ARID1A, a
factor that promotes formation of SWI/SNF-mediated chromatin
remodeling, is a tumor suppressor in gynecologic cancers. Cancer
Res. 71:6718–6727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lichner Z, Scorilas A, White NM, Girgis
AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D and Yousef
GM: The chromatin remodeling gene ARID1A is a new prognostic marker
in clear cell renal cell carcinoma. Am J Pathol. 182:1163–1170.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ozawa Y, Nakamura Y, Fujishima F, Felizola
SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, et al:
Decreased expression of ARID1A contributes to infiltrative growth
of esophageal squamous cell carcinoma. Tohoku J Exp Med.
235:185–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mizuno M, Kikkawa F, Shibata K, Kajiyama
H, Ino K, Kawai M, Nagasaka T and Nomura S: Long-term follow-up and
prognostic factor analysis in clear cell adenocarcinoma of the
ovary. J Surg Oncol. 94:138–143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Itamochi H, Kigawa J and Terakawa N:
Mechanisms of chemoresistance and poor prognosis in ovarian clear
cell carcinoma. Cancer Sci. 99:653–658. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kurman RJ and Shih IeM: The origin and
pathogenesis of epithelial ovarian cancer: A proposed unifying
theory. Am J Surg Pathol. 34:433–443. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Veras E, Mao TL, Ayhan A, Ueda S, Lai H,
Hayran M, Shih IeM and Kurman RJ: Cystic and adenofibromatous clear
cell carcinomas of the ovary: Distinctive tumors that differ in
their pathogenesis and behavior: A clinicopathologic analysis of
122 cases. Am J Surg Pathol. 33:844–853. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B,
Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih
IeM: Loss of ARID1A expression is an early molecular event in tumor
progression from ovarian endometriotic cyst to clear cell and
endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu
CH, Wang TL and Shih IeM: Loss of ARID1A expression correlates with
stages of tumor progression in uterine endometrioid carcinoma. Am J
Surg Pathol. 37:1342–1348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itamochi H, Oumi N, Oishi T, Shoji T,
Fujiwara H, Sugiyama T, Suzuki M, Kigawa J and Harada T: Loss of
ARID1A expression is associated with poor prognosis in patients
with stage I/II clear cell carcinoma of the ovary. Int J Clin
Oncol. 20:967–973. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim MJ, Gu MJ, Chang HK and Yu E: Loss of
ARID1A expression is associated with poor prognosis in small
intestinal carcinoma. Histopathology. 66:508–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo B, Cheung HW, Subramanian A, Sharifnia
T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, et
al: Highly parallel identification of essential genes in cancer
cells. Proc Natl Acad Sci USA. 105:20380–20385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: Implications for development, homeostasis, and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bosse T, ter Haar NT, Seeber LM, v Diest
PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H and Smit
VT: Loss of ARID1A expression and its relationship with PI3K-Akt
pathway alterations, TP53 and microsatellite instability in
endometrial cancer. Mod Pathol. 26:1525–1535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ptak A, Hoffmann M, Gruca I and Barć J:
Bisphenol A induce ovarian cancer cell migration via the MAPK and
PI3K/Akt signalling pathways. Toxicol Lett. 229:357–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jeong SJ, Pise-Masison CA, Radonovich MF,
Park HU and Brady JN: Activated AKT regulates NF-kappaB activation,
p53 inhibition and cell survival in HTLV-1-transformed cells.
Oncogene. 24:6719–6728. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin P, Yi Y, Lu M, Wang M, Yang Y, Lu Y,
Song S, Zheng Z, Deng X and Zhang L: Heat shock protein 90
inhibitor mycoepoxydiene modulates kinase signaling in cervical
cancer cells and inhibits in-vivo tumor growth. Anticancer Drugs.
26:25–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
